Literature DB >> 17169648

Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).

Ashutosh Tewari1, Jay D Raman, Peter Chang, Sandhya Rao, George Divine, Mani Menon.   

Abstract

OBJECTIVES: To report the long-term survival probability in more than 3000 men with localized prostate cancer treated either conservatively or by definitive treatment (radiotherapy or radical prostatectomy).
METHODS: We studied 3159 men with biopsy-confirmed, clinically localized prostate cancer diagnosed from 1980 to 1997. We restricted our analysis to men 75 years of age or younger. The extent of comorbid disease was measured using the Charlson score. The Cox proportional hazards regression model was used to compare long-term survival in patients who were treated conservatively versus survival in patients treated with either radiotherapy or radical prostatectomy.
RESULTS: After adjusting for age, race, tumor grade, comorbid disease, income status, and year of diagnosis, the overall survival rate at 15 years was 35% for conservative management, 50% for radiotherapy, and 65% for radical prostatectomy. The corresponding prostate cancer-specific survival rates were 79%, 87%, and 92%. Patients undergoing radiotherapy or radical prostatectomy had lower overall mortality than patients undergoing conservative management (adjusted relative risk 0.67 for radiotherapy and 0.41 for prostatectomy; P <0.001). The increase in the survival duration was 4.6 years with radiotherapy and 8.6 years with radical prostatectomy.
CONCLUSIONS: The results of this study have shown that compared with conservative management, both radiotherapy and radical prostatectomy increase survival for men with localized prostate cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17169648     DOI: 10.1016/j.urology.2006.08.1059

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

Review 1.  A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.

Authors:  Matthew Kent; Andrew J Vickers
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

2.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

Authors:  Jack Hadley; K Robin Yabroff; Michael J Barrett; David F Penson; Christopher S Saigal; Arnold L Potosky
Journal:  J Natl Cancer Inst       Date:  2010-10-13       Impact factor: 13.506

3.  Correcting the Results of the Wrong Model: Treatment Effects under Early Detection of Cancer.

Authors:  Shih-Yuan Lee; Alex Tsodikov
Journal:  J Stat Theory Pract       Date:  2013-04-05

4.  Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups.

Authors:  Caroline Azelie; Mélanie Gauthier; Céline Mirjolet; Luc Cormier; Etienne Martin; Karine Peignaux-Casasnovas; Gilles Truc; Jérôme Chamois; Philippe Maingon; Gilles Créhange
Journal:  Radiat Oncol       Date:  2012-09-17       Impact factor: 3.481

5.  Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.

Authors:  Yasuhide Miyoshi; Kazumi Noguchi; Masahiro Yanagisawa; Masataka Taguri; Satoshi Morita; Ichiro Ikeda; Kiyoshi Fujinami; Takeshi Miura; Kazuki Kobayashi; Hiroji Uemura
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

6.  Predictive value of the cancer of the prostate risk assessment score for recurrence-free survival after radical prostatectomy in Korea: a single-surgeon series.

Authors:  Won Ik Seo; Pil Moon Kang; Jae Il Chung
Journal:  Korean J Urol       Date:  2014-05-12

7.  Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.

Authors:  Yasuhide Miyoshi; Shuko Yoneyama; Takashi Kawahara; Yusuke Hattori; Jun-ichi Teranishi; Keiichi Kondo; Masatoshi Moriyama; Shigeo Takebayashi; Yumiko Yokomizo; Masahiro Yao; Hiroji Uemura; Kazumi Noguchi
Journal:  BMC Cancer       Date:  2016-02-19       Impact factor: 4.430

8.  New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication.

Authors:  Jennifer H Gunter; Phoebe L Sarkar; Amy A Lubik; Colleen C Nelson
Journal:  Int J Cell Biol       Date:  2013-03-19

9.  Intestinal Permeability of β-Lapachone and Its Cyclodextrin Complexes and Physical Mixtures.

Authors:  Victor Mangas-Sanjuan; Jorge Gutiérrez-Nieto; Magdalena Echezarreta-López; Isabel González-Álvarez; Marta González-Álvarez; Vicente-Germán Casabó; Marival Bermejo; Mariana Landin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.569

10.  Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.

Authors:  Ying Dong; Shook-Fong Chin; Elvin Blanco; Erik A Bey; Wareef Kabbani; Xian-Jin Xie; William G Bornmann; David A Boothman; Jinming Gao
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 13.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.